🔥"Postdoc Night Science Boston" will have its first meeting November 21st at 3:30 at MIT! Postdocs: join us for a session on importing/exporting ideas across research fields! I'll lead this together with @zilberzwige🙏 Register here (limited spots): https://t.co/GYZJvQHfbx

Emergency bulletin! 14 journals have co-published an urgent call for the deployment of microbial solutions against climate catastrophe, by @peixotors et al. https://t.co/yYQZO4Gm6b

“We’re very excited to see what people do with this” AlphaFold3 is open at last

If you want to read something besides election news today, I will suggest my editorial on miRNA therapeutics - the history and possible potential. https://t.co/DZLSk0lpOW

Detailed maps that pinpoint the positions of cells in tumours are offering insights into the development of several cancers and could provide leads for potential treatments

Regulatory reforms will boost African vaccine production and access. Comment from Nicaise Ndembi and colleagues @AfricaCDC @_AfricanUnion https://t.co/Gdd0bquNke

Some great tips for making software public, and usable! (Isn't that the point?)

Our October issue is out now and we're talking about bioremediation, the FDA’s approval of the first T cell therapy for solid tumors, and a new course from CHOP focused on the basics of academic entrepreneurship (which I will be attending next week!) https://t.co/s9mxeOz1Yc

NBT's October issue will be online soon, but you can read this month's editorial a few days early. This month, I'm writing about about how biotech can benefit from new platforms and initiatives around using real-world health data for clinical trials: https://t.co/qIc79yP2iI

Nature Biotechnology's September issue is live! This month, we cover biological foundation models, enzymes that boost "rock weathering" to trap CO2 in soil, and issues using spike-in normalization for ChIP-seq. Read these articles and more here: https://t.co/l64krPiEcU

My editorial at NBT this month discusses avian flu and mpox outbreaks in the wake of COVID19 - and Nature has followed up on this with a nice editorial also. Links to the two articles below: https://t.co/iVgBan6Taz https://t.co/y3UuKGo5cV

An interesting feature in Nature about testing AI in medicine - which is currently messy. There are steps that can be taken to make it less so. https://t.co/LG6LPKgnkh

Nature Biotech's August issue is now live - multi-drug screening in single animals, the patentability of molecular de-extinction, and an editorial written by one of our senior editors on the cultivated meat that's entering your grocery store. https://t.co/21CPF3GlZH

Had a great conversation with Madeline @mad_lancaster about human multi-cellular models of disease, evolution and development for the @NatureBiotech Forum Podcast moderated by Barbara @BCheifet

There is an urgent need for more effective strategies to preselect patients for therapies, mitigating the risk of administering ineffective, potentially harmful drugs and speeding up the process for patients to receive the most effective treatment https://t.co/aL86VDd37Y

Creative approaches, all of which are desperately needed, to address the antimicrobial resistance crisis https://t.co/EafBBNyecc @Nature including #AI, harnessing natural products

Our July issue of Nature Biotechnology is out now! We cover new technology for in vivo lung editing, the use of fungi for bioremediation and how patent expiration date errors can result in hundreds of millions of dollars in added costs to drug prices. https://t.co/eLWCJze84m

Companies are engineering B cells to produce gene-encoded medicines, but clinical proof of concept is needed to convince the doubters that this platform can deliver

Loved this interview in Nature - with fascinating, gorgeous images. https://t.co/tHXVQvAnPc

Check out Nature Biotech's June issue - featuring an editorial on the potential of gene editing for ag bio, news reporting B cells as "biofactories", and a discussion of disclosure of medical AI patents. https://t.co/bn1SOecFDs